Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Walmart Stores Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Walmart Stores Inc trades at $112.98 (market cap $887.64B). The key difference: Walmart Stores Inc is far larger — about 197.7× ACADIA Pharmaceuticals Inc.'s market cap, and Walmart Stores Inc pays a 0.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WMT | |
|---|---|---|
Market Cap | $4.49B | $887.64B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $134.20 |
52-Week Low | $20.06 | $94.40 |
Enterprise Value | $3.69B | $951.09B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Walmart's stock trades at $110.65, down 1.06% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $681.0B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights Walmart's AI initiatives and expansion of drone deliveries, while analyst consensus remains strongly bullish with a $141.64 price target.
The outlook is positive given Walmart's consistent earnings beats and strategic investments in technology, though near-term price pressure and competitive threats from Amazon pose risks. The stock offers a compelling entry point for long-term investors seeking defensive exposure with growth potential, supported by solid fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
